A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Inclusion Criteria: Part 1 * Voluntary written informed consent to participate in the study * Japanese or non-Asian healthy men 18 to \< 50 years at the time of informed consent * BMI 18.5 to \< 30.0 at screening Inclusion Criteria: Part 2 * Voluntary written informed consent to participate in the study * Age 18 years to \< 75 years at the time of informed consent * Weight over 40 kg and BMI 18.5 to \< 35.0 at screening * Patients who meet any of the following criteria 1. Patients who meet the EULAR/ACR 2019 SLE classification criteria and have a diagnosis of SLE by screening 2. Patients with CLE diagnosed by skin biopsy Exclusion Criteria: Part 1 * Current illness requiring treatment * History of or current respiratory disease, heart disease, gastrointestinal disease, kidney disease, liver disease, psychiatric disease, autoimmune disease, or Cancer. * History or of current drug allergy Exclusion Criteria:Part2 * Complications of active lupus nephritis(urinary column (granular column or red blood cell column), hematuria (\>5 red blood cells/high power field, excluding other causes such as stones or infection), proteinuria \>0.5 g/24 h, pyuria (\>5 white blood cells/high power field excluding infection)) or active central nervous lupus (delirium, psychiatric symptoms, seizures, etc.) * Patients with serious complications that are judged by the investigator or sub-investigator to affect the conduct and evaluation of the study. * Patients with bacterial, viral, fungal, or parasitic infections recognized within 28 days prior to obtaining consent * Patients with an infectious disease requiring hospitalization or IV administration of antimicrobial, antiviral, antifungal, or antiparasitic drugs within 24 weeks prior to obtaining consent